Twenty-five FTD patients were enrolled for assays of plasma amyloid β 1–40 (Aβ1–40), Aβ1–42, T-Tau, α-synuclein and TDP-43 using immunomagnetic reduction (IMR). The gene discussed is MAPT; the disease is frontotemporal dementia.